Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine.
Adenylate cyclase-associated protein 1
Colorectal cancer
High-density lipoprotein cholesterol
Paraoxonase-1 activity
Predictive preventive personalized medicine
Resistin
Journal
The EPMA journal
ISSN: 1878-5077
Titre abrégé: EPMA J
Pays: Switzerland
ID NLM: 101517307
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
11
03
2019
accepted:
10
07
2019
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
30
8
2019
Statut:
epublish
Résumé
Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC. Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin's concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism. Plasma resistin and CAP-1 mRNA levels were higher in CRC patients ( Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin's secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.
Sections du résumé
BACKGROUND
BACKGROUND
Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC.
METHODS
METHODS
Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin's concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism.
RESULTS
RESULTS
Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (
CONCLUSIONS
CONCLUSIONS
Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin's secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.
Identifiants
pubmed: 31462946
doi: 10.1007/s13167-019-00178-x
pii: 178
pmc: PMC6695467
doi:
Types de publication
Journal Article
Langues
eng
Pagination
307-316Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflicts of interest.
Références
Biochem Biophys Res Commun. 2003 Sep 19;309(2):286-90
pubmed: 12951047
Am J Hum Genet. 2004 Oct;75(4):678-86
pubmed: 15338456
Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1070-4
pubmed: 17998831
World J Gastroenterol. 2009 Jan 21;15(3):257-63
pubmed: 19140224
Regul Pept. 2009 Oct 9;157(1-3):57-63
pubmed: 19445973
J Cell Mol Med. 2010 Jun;14(6B):1419-31
pubmed: 19754671
Diabetologia. 2010 Apr;53(4):795-7
pubmed: 20131043
Cancer Sci. 2010 May;101(5):1286-91
pubmed: 20331631
Trends Endocrinol Metab. 2011 Jul;22(7):259-65
pubmed: 21497511
Clin Chim Acta. 2012 Apr 11;413(7-8):760-4
pubmed: 22296675
EPMA J. 2012 Nov 01;3(1):14
pubmed: 23116135
PLoS One. 2013;8(1):e53916
pubmed: 23349764
J Cell Sci. 2013 Aug 1;126(Pt 15):3249-58
pubmed: 23908377
J Clin Res Pediatr Endocrinol. 2013 Sep 10;5(3):189-93
pubmed: 24072088
Biomark Med. 2014;8(1):107-18
pubmed: 24325232
Int J Mol Cell Med. 2013 Summer;2(3):143-50
pubmed: 24551805
Cell Metab. 2014 Mar 4;19(3):484-97
pubmed: 24606903
World J Gastroenterol. 2014 May 14;20(18):5177-90
pubmed: 24833848
J Biomed Sci. 2014 Jun 14;21:59
pubmed: 24929539
Diabetes Metab Syndr. 2015 Oct-Dec;9(4):266-70
pubmed: 25311818
Atherosclerosis. 2014 Dec;237(2):652-60
pubmed: 25463101
Cancer Causes Control. 2015 Feb;26(2):257-268
pubmed: 25488827
EPMA J. 2015 Apr 15;6(1):9
pubmed: 25908947
Adv Cancer Res. 2015;128:173-96
pubmed: 26216633
Sci Rep. 2016 May 13;6:25933
pubmed: 27173014
Sci Rep. 2016 Jul 29;6:30889
pubmed: 27468698
Biomed Res Int. 2016;2016:7367485
pubmed: 27642602
EPMA J. 2016 Oct 25;7:23
pubmed: 27800037
J Clin Endocrinol Metab. 2017 Mar 1;102(3):884-892
pubmed: 27929711
EPMA J. 2017 Mar 9;8(1):51-60
pubmed: 28620443
BMC Biol. 2017 Jun 29;15(1):53
pubmed: 28662662
Eur J Clin Invest. 2017 Sep;47(9):659-666
pubmed: 28707728
Oncogene. 2018 Feb 1;37(5):589-600
pubmed: 28991224
J Cancer. 2018 Jan 1;9(3):494-501
pubmed: 29483954
EPMA J. 2018 Feb 21;9(1):77-102
pubmed: 29515689
Genet Test Mol Biomarkers. 2018 Apr;22(4):209-217
pubmed: 29641286
EPMA J. 2018 Mar 26;9(2):113-123
pubmed: 29896312
Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2709-2716
pubmed: 30360595
Biochem Med (Zagreb). 2018 Oct 15;28(3):030703
pubmed: 30429670
Clin Biochem. 2019 Jan;63:32-38
pubmed: 30500525